Form 4: Pure Bioscience CEO Acquires Options in Company Stock
SEC Form 4 Filing
Robert Bartlett, CEO and President of Pure Bioscience, acquired options to purchase company stock on August 20, 2024.
Summary
- Robert Bartlett, the CEO and President of Pure Bioscience, acquired options to purchase shares of the company's common stock on August 20, 2024.
- He acquired options for 155,000 shares at an exercise price of $0.07, which vest in four equal installments starting November 20, 2024, and ending August 20, 2025.
- Bartlett also acquired fully vested options for 500,000 shares at an exercise price of $0.07 on the same date.
- Both sets of options expire on August 20, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which doesn't inherently indicate positive or negative news.
Positives
- The CEO's acquisition of stock options may signal confidence in the company's future performance.
Industry Context
Insider transactions are closely watched as indicators of management's confidence in the company's prospects. Option grants are a common form of executive compensation.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in publicly traded companies.
- The vesting schedule and exercise price are within the range of industry norms, but without further context on Bartlett's overall compensation package, it's difficult to make a precise comparison.
- Companies like Ecolab and Steris, which operate in related sectors, also utilize stock options as part of their executive compensation plans.
Stakeholder Impact
- The acquisition of stock options by the CEO could be viewed positively by shareholders as it aligns management's interests with theirs.
Key Dates
| Date | Description |
|---|---|
| 08/20/2024 | Date of the stock option grants. |
| 11/20/2024 | First vesting date for 155,000 option shares. |
| 02/20/2025 | Second vesting date for 155,000 option shares. |
| 05/20/2025 | Third vesting date for 155,000 option shares. |
| 08/20/2025 | Final vesting date for 155,000 option shares. |
| 08/20/2034 | Expiration date for all options granted. |
| 08/22/2024 | Date of Form 4 filing. |
Keywords
stock options, Form 4, Robert Bartlett, CEO, Pure Bioscience, PURE, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.